JAK1 and non-small cell lung carcinoma: Although there remains extensive preclinical promise of targeting the JAK/STAT pathway for EGFR-mutated NSCLC [19–21, 23–25], we observed that the preliminary efficacy of the combination of JAK1/2 inhibitor, momelotinib, and erlotinib was similar to erlotinib monotherapy, including an ORR of 54.5% (90% CI 27.1–80.0) and a median PFS of 9.2 months (90% CI 6.2–12.4) [2, 33, 34].